{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:55:20Z","timestamp":1769885720841,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272045"],"award-info":[{"award-number":["82272045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801740"],"award-info":[{"award-number":["81801740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Program of Ministry of Industry and Information Technology of China Technology of China","award":["CEIEC-2022-ZM02-0219"],"award-info":[{"award-number":["CEIEC-2022-ZM02-0219"]}]},{"name":"Hunan Provincial Science Fund for Distinguished Young Scholars","award":["2024JJ2094"],"award-info":[{"award-number":["2024JJ2094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07574-8","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:29:34Z","timestamp":1759483774000},"page":"1754-1764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-tracer PET\/CT with [68Ga]Ga-PSMA\u2212617 and [68Ga]Ga-RM26 improves early prediction of biochemical failure in prostate cancer: a prospective phase II trial"],"prefix":"10.1007","volume":"53","author":[{"given":"Jinhui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1633-463X","authenticated-orcid":false,"given":"Yujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8943","authenticated-orcid":false,"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"7574_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7574_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215927","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Prostate cancer treatment - China\u2019s perspective. Cancer Lett. 2022. https:\/\/doi.org\/10.1016\/j.canlet.2022.215927.","journal-title":"Cancer Lett"},{"key":"7574_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28162","author":"N Shao","year":"2013","unstructured":"Shao N, et al. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int J Cancer. 2013. https:\/\/doi.org\/10.1002\/ijc.28162.","journal-title":"Int J Cancer"},{"key":"7574_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.06.003","author":"P Qi","year":"2013","unstructured":"Qi P, et al. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen\u2009<\u20092.5 ng\/ml and 2.5-4 ng\/ml. Urol Oncol. 2013. https:\/\/doi.org\/10.1016\/j.urolonc.2012.06.003.","journal-title":"Urol Oncol"},{"key":"7574_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13808","author":"A Abdel Raheem","year":"2018","unstructured":"Abdel Raheem A, et al. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: analysis of 359 cases with a median follow-up period of 26 months. Int J Urol. 2018. https:\/\/doi.org\/10.1111\/iju.13808.","journal-title":"Int J Urol"},{"key":"7574_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(02)02526-8","author":"SJ Freedland","year":"2003","unstructured":"Freedland SJ, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003. https:\/\/doi.org\/10.1016\/s0090-4295(02)02526-8.","journal-title":"Urology"},{"key":"7574_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2009.02401.x","author":"T Inagaki","year":"2009","unstructured":"Inagaki T, et al. PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy. Int J Urol. 2009. https:\/\/doi.org\/10.1111\/j.1442-2042.2009.02401.x.","journal-title":"Int J Urol"},{"key":"7574_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00063","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Metabolic syndrome is not associated with prostate cancer recurrence: a retrospective analysis of a Chinese cohort. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00063.","journal-title":"Front Oncol"},{"key":"7574_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e103bf","author":"D Cao","year":"2010","unstructured":"Cao D, et al. The gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. Am J Surg Pathol. 2010. https:\/\/doi.org\/10.1097\/PAS.0b013e3181e103bf.","journal-title":"Am J Surg Pathol"},{"key":"7574_CR10","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1719_21","author":"E Rani","year":"2023","unstructured":"Rani E, Nibhoria S, Nagpal N. Outlook of Gleason score in prostate carcinoma and correlation with PSA levels: a study in a tertiary care hospital. J Cancer Res Ther. 2023. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1719_21.","journal-title":"J Cancer Res Ther"},{"key":"7574_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.07.027","author":"E Mazzone","year":"2022","unstructured":"Mazzone E, et al. Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups. Eur Urol. 2022. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.027.","journal-title":"Eur Urol"},{"key":"7574_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05245-y","author":"F Ceci","year":"2021","unstructured":"Ceci F, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, et al. PSMA PET\/CT: joint EANM procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05756-2","author":"MJ Roberts","year":"2022","unstructured":"Roberts MJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05756-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR15","doi-asserted-by":"publisher","unstructured":"Roberts MJ, et al. (68)Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-020-04944-2.","DOI":"10.1007\/s00259-020-04944-2"},{"key":"7574_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00326-7","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024. https:\/\/doi.org\/10.1016\/s1470-2045(24)00326-7.","journal-title":"Lancet Oncol"},{"issue":"11","key":"7574_CR17","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980601)82:11%3C;2256::aid-cncr22%3E;3.0.co;2-s.","journal-title":"Cancer"},{"key":"7574_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06142-2","author":"X Gao","year":"2023","unstructured":"Gao X, et al. A prospective comparative study of [(68)Ga]Ga-RM26 and [(68)Ga]Ga-PSMA-617 PET\/CT imaging in suspicious prostate cancer. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06142-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101213","author":"TC Case","year":"2021","unstructured":"Case TC, et al. Blocking GRP\/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer. Transl Oncol. 2021. https:\/\/doi.org\/10.1016\/j.tranon.2021.101213.","journal-title":"Transl Oncol"},{"key":"7574_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242128","author":"DG Kim","year":"2024","unstructured":"Kim DG, et al. GRPR drives metastasis via CRABP2 and FNDC4 pathways in lung adenocarcinoma. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13242128.","journal-title":"Cells"},{"key":"7574_CR21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188011","author":"C Morgat","year":"2017","unstructured":"Morgat C, et al. Expression of Gastrin-Releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.116.188011.","journal-title":"J Nucl Med"},{"key":"7574_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.08.011","author":"KA Touijer","year":"2019","unstructured":"Touijer KA, et al. Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer. Eur Urol Oncol. 2019. https:\/\/doi.org\/10.1016\/j.euo.2018.08.011.","journal-title":"Eur Urol Oncol"},{"key":"7574_CR23","doi-asserted-by":"publisher","DOI":"10.2307\/2531910","author":"E Lakatos","year":"1988","unstructured":"Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988. https:\/\/doi.org\/10.2307\/2531910.","journal-title":"Biometrics"},{"key":"7574_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005724","author":"Y Li","year":"2025","unstructured":"Li Y, et al. Using mpmri, PSMA, and GRPR PET to assess focal therapy eligibility and plan treatment in biopsy-proven low-\/intermediate-risk prostate cancer: a whole-mount pathology-based study. Clin Nucl Med. 2025. https:\/\/doi.org\/10.1097\/rlu.0000000000005724.","journal-title":"Clin Nucl Med"},{"key":"7574_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05636-1","author":"DX Qiu","year":"2022","unstructured":"Qiu DX, et al. Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-021-05636-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR26","unstructured":"Edge S, Compton BD, Fritz C, Greene A, Trotti FA.\u00a0AJCC CANCER STAGING MANUAL seventh edition 2010.\u00a0https:\/\/www.facs.org\/media\/j30havyf\/ajcc_7thed_cancer_staging_manual.pdf. Springer-, New York, NY."},{"key":"7574_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.07.017","author":"H Ross-Adams","year":"2015","unstructured":"Ross-Adams H, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine. 2015. https:\/\/doi.org\/10.1016\/j.ebiom.2015.07.017.","journal-title":"EBioMedicine"},{"key":"7574_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020290","author":"S Lage-Vickers","year":"2022","unstructured":"Lage-Vickers S, et al. Exploiting interdata relationships in prostate cancer proteomes: clinical significance of HO-1 interactors. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11020290.","journal-title":"Antioxidants"},{"key":"7574_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09331-8","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, et al. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/s12885-022-09331-8.","journal-title":"BMC Cancer"},{"key":"7574_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.605810","author":"K Guo","year":"2021","unstructured":"Guo K, et al. A novel risk factor model based on Glycolysis-associated genes for predicting the prognosis of patients with prostate cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.605810.","journal-title":"Front Oncol"},{"key":"7574_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61253-7","author":"M Bolla","year":"2012","unstructured":"Bolla M, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012. https:\/\/doi.org\/10.1016\/s0140-6736(12)61253-7.","journal-title":"Lancet"},{"key":"7574_CR32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100784","author":"J Delgado","year":"2014","unstructured":"Delgado J, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014. https:\/\/doi.org\/10.3324\/haematol.2013.100784.","journal-title":"Haematologica"},{"key":"7574_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01116-3","author":"L Xiao","year":"2024","unstructured":"Xiao L, et al. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. EJNMMI Res. 2024. https:\/\/doi.org\/10.1186\/s13550-024-01116-3.","journal-title":"EJNMMI Res"},{"key":"7574_CR34","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.11085","author":"G Rodrigues","year":"2012","unstructured":"Rodrigues G, et al. Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J. 2012. https:\/\/doi.org\/10.5489\/cuaj.11085.","journal-title":"Can Urol Assoc J"},{"key":"7574_CR35","doi-asserted-by":"publisher","unstructured":"D\u2019Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998. https:\/\/doi.org\/10.1001\/jama.280.11.969.","DOI":"10.1001\/jama.280.11.969"},{"key":"7574_CR36","doi-asserted-by":"publisher","unstructured":"Hofman MS, et al. Baseline nodal status on (68)Ga-PSMA-11 positron emission tomography\/computed tomography in men with Intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the ProPSMA trial. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.11.006.","DOI":"10.1016\/j.euo.2024.11.006"},{"key":"7574_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.003","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani G, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol. 2010. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.003.","journal-title":"Eur Urol"},{"key":"7574_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06734-6","author":"T Li","year":"2024","unstructured":"Li T, et al. Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06734-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7574_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00818-2","author":"H Wang","year":"2021","unstructured":"Wang H, et al. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Res. 2021. https:\/\/doi.org\/10.1186\/s13550-021-00818-2.","journal-title":"EJNMMI Res"},{"key":"7574_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aag3326","author":"LA Caromile","year":"2017","unstructured":"Caromile LA, et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal. 2017. https:\/\/doi.org\/10.1126\/scisignal.aag3326.","journal-title":"Sci Signal"},{"key":"7574_CR41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171052","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis C, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018. https:\/\/doi.org\/10.1084\/jem.20171052.","journal-title":"J Exp Med"},{"key":"7574_CR42","doi-asserted-by":"publisher","unstructured":"Hyv\u00e4kk\u00e4 A, et al. More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-Specific membrane antigen (PSMA) in metastatic prostate cancer and beyond. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092244.","DOI":"10.3390\/cancers13092244"},{"key":"7574_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22594-1","author":"S Bravaccini","year":"2018","unstructured":"Bravaccini S, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-22594-1.","journal-title":"Sci Rep"},{"key":"7574_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15710","author":"YJL Bodar","year":"2022","unstructured":"Bodar YJL, et al. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with oncological outcomes in patients with prostate cancer. BJU Int. 2022. https:\/\/doi.org\/10.1111\/bju.15710.","journal-title":"BJU Int"},{"key":"7574_CR45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263889","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, et al. Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.122.263889.","journal-title":"J Nucl Med"},{"key":"7574_CR46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259630","author":"L Baratto","year":"2021","unstructured":"Baratto L, et al. PSMA- and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.259630.","journal-title":"J Nucl Med"},{"key":"7574_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.005","author":"AB Weiner","year":"2024","unstructured":"Weiner AB, et al. Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.005.","journal-title":"Eur Urol"},{"key":"7574_CR48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267301","author":"DH Angappulige","year":"2024","unstructured":"Angappulige DH, et al. Prostate-specific membrane antigen-targeted imaging and its correlation with HOXB13 expression. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.267301.","journal-title":"J Nucl Med"},{"key":"7574_CR49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.153023","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015. https:\/\/doi.org\/10.2967\/jnumed.114.153023.","journal-title":"J Nucl Med"},{"key":"7574_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01302-x","author":"TST Damiana","year":"2025","unstructured":"Damiana TST, et al. Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells. EJNMMI Res. 2025. https:\/\/doi.org\/10.1186\/s13550-025-01302-x.","journal-title":"EJNMMI Res"},{"key":"7574_CR51","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2012_029","author":"S Nagasaki","year":"2012","unstructured":"Nagasaki S, et al. Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor \u03b2cx in human prostate carcinoma. Neoplasma. 2012_. https:\/\/doi.org\/10.4149\/neo_2012_029.","journal-title":"Neoplasma"},{"key":"7574_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0222-3","author":"CY Cheng","year":"2020","unstructured":"Cheng CY, et al. Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem\/progenitor cells. Oncogenesis. 2020. https:\/\/doi.org\/10.1038\/s41389-020-0222-3.","journal-title":"Oncogenesis"},{"key":"7574_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0517-6","author":"R Schollhammer","year":"2019","unstructured":"Schollhammer R, et al. Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples. EJNMMI Res. 2019. https:\/\/doi.org\/10.1186\/s13550-019-0517-6.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07574-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:11Z","timestamp":1769834591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07574-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7574"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07574-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Xiangya Hospital, Central South University (201909253) and ethics review board (NCT05073653, Registration Date: 2021-10-11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and photograph.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"AR and KS are editors of the journal European Journal of Nuclear Medicine and Molecular Imaging. The other authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}